

CHRONIC HEART FAILURE IN RUSSIAN FEDERATION.

Russian Journal of Cardiology

, 7-13

DOI: 10.15829/1560-4071-2016-8-7-13

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A Translational Model of Chronic Heart Failure. Bulletin of Experimental Biology and Medicine, 2019, 167, 706-710. | 0.8 | 1 |
| 2 | Angiogenesis in Patients with Chronic Heart Failure: Focus on Endothelial Vascular Growth Factor, Pentraxin-3 and Transforming Growth Factor Beta. Rational Pharmacotherapy in Cardiology, 2020, 16, 439-448. | 0.8 | 0 |
| 3 | Possibilities of Ultrasound Diagnosis of Sarcopenia in Elderly Patients with Chronic Heart Failure. Advances in Gerontology, 2020, 10, 182-186. | 0.4 | 0 |
| 5 | Chronic heart failure and adherence to medication: methods for assessing adherence to therapy and unresolved issues. Clinicist, 2021, 14, 18-28. | 0.5 | 2 |
| 6 | Speckle-tracking echocardiography in the early diagnosis of heart failure after ST-segment elevation myocardial infarction. Russian Journal of Cardiology, 2021, 26, 4088. | 1.4 | 2 |
| 7 | Risk stratification of sudden cardiac death in heart failure patients: is left ventricular ejection fraction alone sufficient?. Russian Journal of Cardiology, 2021, 26, 3959. | 1.4 | 10 |
| 8 | Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2569. | 1.4 | 2 |
| 9 | Diagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease. Complex Issues of Cardiovascular Diseases, 2021, 10, 6-15. | 0.5 | 1 |
| 11 | The Value of Biomarkers in the Diagnosis and Prognosis of Heart Failure in Older Age. Russian Archives of Internal Medicine, 2021, 11, 98-110. | 0.2 | 4 |
| 12 | Advanced heart failure. Bulletin of Siberian Medicine, 2021, 20, 129-146. | 0.3 | 3 |
| 13 | Psychosocial adaptation to chronic heart failure in patients with coronary heart disease. Kazan Medical Journal, 2021, 102, 156-166. | 0.2 | 0 |
| 14 | Carbohydrate metabolism disorders in patients with heart failure: data from the local registry. Russian Journal of Cardiology, 2021, 26, 4330. | 1.4 | 3 |
| 15 | Management of Patients with Chronic Heart Failure and Diabetes Mellitus. Rational Pharmacotherapy in Cardiology, 2021, 17, 341-350. | 0.8 | 1 |
| 16 | Role of macrophages in cardiorenal syndrome development in patients with myocardial infarction. Russian Journal of Cardiology, 2021, 26, 4309. | 1.4 | 3 |
| 17 | Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives. Russian Journal of Cardiology, 2021, 26, 4436. | 1.4 | 3 |
| 18 | Possibilities of Evaluating the Dynamics of Left Ventricular Perfusion and Contractility in Patients with Chronic Heart Failure after Implantation of a Heart Contractility Modulator Using Perfusion Single-Photon Emission Computed Tomography. Rational Pharmacotherapy in Cardiology, 2021, 17, 263-269. | 0.8 | 0 |
| 19 | Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Russian Journal of Cardiology, 2021, 26, 4368. | 1.4 | 10 |
| 22 | Clinical, laboratory and instrumental evaluation of structural and functional changes of the liver in patients with heart failure. HERALD of North-Western State Medical University Named After I I Mechnikov, 2021, 13, 27-37. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 23 | Retrospective analysis of electronic health records of patients with heart failure: the first Russian experience. Russian Journal of Cardiology, 2021, 26, 4502. | 1.4 | 7 |
| 24 | Clinical characteristics and treatment of outpatients with chronic heart failure in the Moscow Region. AlĖmanah KliniĖskoj Mediciny, 2021, 49, 125-131. | 0.3 | 1 |
| 25 | The role of thyrostatic agents in the treatment of chronic heart failure patients with comorbid coronary artery disease and thyrotoxicosis. AlĖmanah KliniĖskoj Mediciny, 2021, 49, 132-141. | 0.3 | 2 |
| 26 | Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares. Russian Journal of Cardiology, 2021, 26, 4534. | 1.4 | 1 |
| 27 | Sleep-related breathing disorders in patients with heart failure: classification, epidemiology and pathophysiology. Part I. Russian Journal of Cardiology, 2021, 26, 4386. | 1.4 | 0 |
| 28 | Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology, 2021, 26, 4490. | 1.4 | 19 |
| 29 | Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial âœ€A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trialâœ€R. Russian Journal of Cardiology, 2021, 26, 4562. | 1.4 | 3 |
| 31 | Prognostic value of secondary hyperaldosteronism in patients with chronic heart failure with preserved ejection fraction. Medical Herald of the South of Russia, 2021, 12, 81-91. | 0.4 | 1 |
| 33 | Evaluation of the long-term effectiveness of cardiac resynchronization therapy. Russian Journal of Cardiology, 2021, 26, 4531. | 1.4 | 6 |
| 34 | Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction. Fundamental and Clinical Medicine, 2021, 6, 46-55. | 0.3 | 0 |
| 35 | Electrocardiographic and imaging methods in risk stratification of sudden cardiac death in patients with chronic heart failure. Journal of Arrhythmology, 2021, 28, 28-36. | 0.2 | 1 |
| 36 | Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients. Eurasian Heart Journal, 2021, , 28-35. | 0.8 | 0 |
| 37 | The Effect of Angiotensin Receptor Inhibitors and Nephilysin on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 298-306. | 0.6 | 0 |
| 38 | Clinical, pathogenetic, and diagnostic features of heart failure in patients with coronary heart disease and thyrotoxicosis. Russian Journal of Cardiology, 2019, , 28-34. | 1.4 | 2 |
| 39 | Features of chronic heart failure depending on the left ventricular ejection fraction. Russian Journal of Cardiology, 2019, , 7-11. | 1.4 | 8 |
| 40 | 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083. | 1.4 | 229 |
| 41 | Assessment of prevalence and monitoring of outcomes in patients with heart failure in Russia. Russian Journal of Cardiology, 2020, 25, 4204. | 1.4 | 7 |
| 42 | Young ambulatory patients with cardiovascular diseases: age and gender characteristics, comorbidity, medication and outcomes (according to RECVASA register). Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 99-106. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 43 | Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2454. | 1.4 | 6 |
| 44 | Diagnostic, prognostic and therapeutic potential of 6-minute walk test in patients with heart failure. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2460. | 1.4 | 3 |
| 45 | 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083. | 1.4 | 32 |
| 55 | Association Between Hyperaldosteronemia and Electrophysiological Myocardial Activity in Heart Failure with Preserved Ejection Fraction. Russian Archives of Internal Medicine, 2020, 10, 382-389. | 0.2 | 1 |
| 56 | Decision rule for stratification of patients with chronic heart failure of functional class II and III. Bulletin of Siberian Medicine, 2020, 19, 101-107. | 0.3 | 2 |
| 57 | Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data) Tj ETQq1 1 0,784314 rgBT /Overl | 0.8 | 0 |
| 58 | Heart failure and senile asthenia syndrome. Meditsinskiy Sovet, 2018, , 72-79. | 0.5 | 3 |
| 59 | Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure. Medical Herald of the South of Russia, 2018, 9, 73-80. | 0.4 | 3 |
| 60 | Rationale of specialized medical care for patients with chronic heart failure in the Russian Federation. Å¼no-Rossiiskij Å¼urnal Terapevtičeskoj Praktiki, 2020, 1, 44-53. | 0.3 | 2 |
| 61 | Prognostic impact of uric acid in patients with acute decompensated heart failure. Terapevtičeskii Arkhiv, 2021, 93, 1066-1072. | 0.8 | 0 |
| 62 | Role of catestatin in development and decompensation of heart failure: a literature review. Russian Journal of Cardiology, 2021, 26, 4492. | 1.4 | 2 |
| 63 | Nitric oxide â€” soluble guanylate cyclase â€” cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3035. | 1.4 | 2 |
| 64 | Management of heart failure patients in Russia: perspectives and realities of the second decade of the XXI century. Russian Journal of Cardiology, 2021, 26, 4658. | 1.4 | 5 |
| 65 | ICD-10 code-based definition of heart failure in Saint Petersburg electronic health records: prevalence, health care utilization and outcomes. Russian Journal of Cardiology, 2021, 26, 4621. | 1.4 | 4 |
| 66 | Comparative efficacy of enalapril and valsartan in heart failure with mid-range ejection fraction. Kazan Medical Journal, 2021, 102, 614-620. | 0.2 | 0 |
| 67 | Multimarker approach for assessing efficiency of cardiac resynchronization therapy in patients with sinus rhythm. Journal of Arrhythmology, 0, 28, 17-24. | 0.2 | 0 |
| 68 | ULTRASOUND CRITERIA OF THE DIURETIC THERAPY EFFECTIVENESS IN CHRONIC HEART FAILURE. Siberian Medical Journal, 2018, 33, 51-55. | 0.3 | 2 |
| 71 | The effects of angiotensin-converting enzyme inhibitors in heart recipients: a single center experience. Vestnik Transplantologii i Iskusstvennykh Organov, 2019, 20, 14-21. | 0.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 72 | Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 36-41. | 0.8 | 3 |
| 73 | Influence of beta-blockers on mechanical dyssynchrony and cardiac remodeling in patients with ischemic chronic heart failure in the setting of revascularization. <i>Research Results in Pharmacology</i> , 2019, 5, 1-13. | 0.4 | 1 |
| 75 | Heart failure. The current state of the problem: achievements, frustrations, hopes and prospects. <i>Meditsinskiy Sovet</i> , 2019, , 14-19. | 0.5 | 0 |
| 76 | Cardiac resynchronization therapy in patients with chronic heart failure: the view of a therapist, cardiologist. <i>Cardiosomatics</i> , 2019, 10, 13-29. | 0.4 | 1 |
| 77 | Epidemiological and nosological structure of patients with chronic heart failure according to institutions of tertiary level of healthcare of the Kyrgyz Republic. <i>Heart Vessels and Transplantation</i> , 0, 3, 134. | 0.0 | 1 |
| 78 | Patient compliance and physicians' adherence to guidelines on heart failure with reduced ejection fraction. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2398. | 1.4 | 3 |
| 81 | Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. <i>Russian Journal of Cardiology</i> , 2020, 25, 3870. | 1.4 | 6 |
| 82 | Multimarker approach for assessing efficiency of cardiac resynchronization therapy in patients with sinus rhythm. <i>Journal of Arrhythmology</i> , 2020, 27, 21-29. | 0.2 | 2 |
| 83 | COMPARATIVE EVALUATION OF AUTONOMIC REACTIVITY IN PATIENTS WITH CHRONIC HEART FAILURE AND TYPE 2 DIABETES MELLITUS WITH DIABETIC AUTONOMIC CARDIAC NEUROPATHY. , 2020, 74, 130-134. | | 0 |
| 84 | Current Clinical and Pharmacological Approaches to the Prescription of Loop Diuretics in Patients with Chronic Heart Failure. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 595-600. | 0.8 | 1 |
| 85 | EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). <i>Eurasian Heart Journal</i> , 2020, , 6-76. | 0.8 | 6 |
| 87 | Calcium metabolism, arterial stiffness and 24-hour blood pressure monitoring data in postmenopausal women with magnesium deficiency, hypertension, and heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 3984. | 1.4 | 1 |
| 88 | Early Predictors of Heart Failure Progression in Patients After Myocardial Infarction. <i>Kardiologiya</i> , 2020, 60, 84-93. | 0.7 | 4 |
| 90 | Chronic heart failure: actual aspects of treatment in real clinical practice. <i>Meditsinskiy Sovet</i> , 2019, , 50-58. | 0.5 | 0 |
| 91 | Clinical significance and prospects of using ST2 in ischemic heart failure patients. <i>Siberian Medical Journal</i> , 2020, 35, 89-97. | 0.3 | 0 |
| 92 | Evaluating Adherence to Medical Therapy in Patients with Chronic Heart Failure: Design and First Results of the COMPLIANCE Study. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 571-578. | 0.8 | 4 |
| 93 | Associations of NT-proBNP and hepcidin levels with clinical and laboratory parameters in patients with heart failure with various severity of left ventricular systolic dysfunction. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2587. | 1.4 | 2 |
| 94 | New approach for the rehabilitation of patients with chronic heart failure associated with type 2 diabetes. <i>Meditsinskiy Sovet</i> , 2020, , 40-47. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 95 | Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases. Russian Journal of Cardiology, 2020, 25, 4142. | 1.4 | 3 |
| 96 | Fluid retention in patients with paroxysmal and permanent atrial fibrillation and heart failure. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2402. | 1.4 | 1 |
| 97 | Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2652. | 1.4 | 0 |
| 99 | Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 3068. | 1.4 | 2 |
| 100 | Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice. Russian Journal of Cardiology, 2021, 26, 4699. | 1.4 | 1 |
| 101 | Alternative Options for the Nutritional Status of Patients with Chronic Heart Failure: CHF Phenotype with Sarcopenic Obesity. Russian Archives of Internal Medicine, 2021, 11, 442-446. | 0.2 | 0 |
| 102 | Clinical and demographic characteristics of patients with congestive heart failure and implanted devices for cardiac resynchronization therapy. The Siberian Scientific Medical Journal, 2021, 41, 100-108. | 0.3 | 0 |
| 103 | Melatonin and cardiovascular disease: from mechanisms of action to potential clinical use (literature) Tj ETQq1 1 0.784314 rgBT /Overlo | 1.4 | 1 |
| 104 | Echocardiography parameter for evaluation of various effects of cardiac resynchronization therapy. Kardiologiya i Serdechno-Sosudistaya Khirurgiya, 2022, 15, 19. | 0.3 | 2 |
| 105 | Chronic heart failure: evolution of etiology, prevalence and mortality over the past 20 years. Terapevticheskii Arkhiv, 2022, 94, 5-8. | 0.8 | 5 |
| 106 | Levels of angiogenesis markers in patients with different heart failure phenotypes. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3230. | 1.4 | 0 |
| 107 | Malnutrition as a factor aggravating the heart failure course in the elderly and senile age. Russian Journal of Cardiology, 2022, 27, 4583. | 1.4 | 3 |
| 108 | Cardio-cerebral syndrome in patients with chronic heart failure. Russian Neurological Journal, 2022, 27, 26-30. | 0.3 | 0 |
| 109 | Predictors of cardiovascular complications in patients with arterial hypertension and comorbid pathology. Systemic Hypertension, 2021, 18, 180-185. | 0.6 | 0 |
| 110 | Treatment strategies for patients with atrial fibrillation and chronic heart failure. Terapevticheskii Arkhiv, 2021, 93, 1545-1550. | 0.8 | 1 |
| 111 | Ultrasound diagnosis of congestion in the pulmonary and systemic circulations in patients with atrial fibrillation and chronic heart failure. Russian Open Medical Journal, 2021, 10, . | 0.3 | 1 |
| 112 | On formation of padder syndrome. Medical Alphabet, 2021, , 30-33. | 0.2 | 0 |
| 113 | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure. Russian Journal of Cardiology, 2022, 26, 4800. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 114 | Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russian Journal of Cardiology, 2022, 26, 4791. | 1.4 | 1 |
| 115 | Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv, 2021, 93, 1491-1497. | 0.8 | 6 |
| 116 | Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. Consilium Medicum, 2022, 24, 28-35. | 0.3 | 0 |
| 117 | Pentraxin-3 – a promising biological marker in heart failure: literature review. Consilium Medicum, 2022, 24, 53-59. | 0.3 | 2 |
| 118 | Chronic heart failure – modification of treatment paradigm. Consilium Medicum, 2022, 24, 13-19. | 0.3 | 1 |
| 119 | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. Russian Journal of Cardiology, 2022, 27, 4945. | 1.4 | 1 |
| 120 | Effect of β -blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction. Bulletin of Siberian Medicine, 2022, 21, 35-46. | 0.3 | 0 |
| 121 | Physicians' adherence to the guidelines on the chronic heart failure diagnosis and treatment. Kardiologiya, 2022, 62, 53-61. | 0.7 | 3 |
| 122 | Chronic and acute decompensated heart failure: topical issues. Complex Issues of Cardiovascular Diseases, 2022, 11, 184-195. | 0.5 | 3 |
| 123 | Evaluation of the Effect of Comorbidity on the Efficacy and Safety of β -Lactam Antibiotics in Patients with Community-Acquired Pneumonia. Safety and Risk of Pharmacotherapy, 2022, 10, 96-109. | 0.2 | 0 |
| 124 | Using pulmonary vein diameters for prescribing diuretic therapy and estimating its effectiveness in heart failure with preserved ejection fraction outpatients. Future Cardiology, 0, , . | 1.2 | 0 |
| 125 | Adrenomedullin is a biological marker of heart failure: review of modern literature; Amina M. Alieva*1, Natalia. Cardiosomatics, 2022, 13, 64-69. | 0.4 | 2 |
| 126 | Electrocardiographic signs of impaired depolarization (fragmented QRS, early ventricular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 267 Td (Cardiology, 2022, 27, 5113. | 1.4 | 0 |
| 127 | Electrocardiographic Patterns of Depolarization Abnormalities Help to Identify Reduced Left Ventricular Ejection Fraction. Diagnostics, 2022, 12, 2020. | 2.6 | 0 |
| 128 | Structural and functional features of the heart and the dynamics of biomarkers in the progression of chronic heart failure with a moderately reduced ejection fraction of the left ventricle in patients with diabetes mellitus. Cardiosomatics, 2022, 13, 87-93. | 0.4 | 0 |
| 129 | Adherence to therapy and the risk of cardiovascular events in patients with heart failure: data from the outpatient registry. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 21, 3389. | 1.4 | 1 |
| 130 | Heart failure with preserved left ventricular ejection fraction: a comprehensive phenotype-based approach to diagnosis and treatment. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 627. | 0.3 | 0 |
| 131 | Interleukin-1 is a Biological Marker in Heart Failure. Russian Archives of Internal Medicine, 2022, 12, 422-429. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 132 | Catestatin – a promising biological marker for heart failure: A review. <i>Consilium Medicum</i> , 2022, 24, 726-731. | 0.3 | 0 |
| 133 | Twenty-year changes in the clinical and echocardiographic characteristics of patients with early postinfarction remodeling after primary ST-segment elevation myocardial infarction. <i>Russian Journal of Cardiology</i> , 2023, 27, 4951. | 1.4 | 0 |
| 134 | The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation. <i>Rational Pharmacotherapy in Cardiology</i> , 2023, 18, 662-668. | 0.8 | 0 |
| 135 | Dynamics of structural and functional characteristics of the heart in patients after myocardial infarction with ST segment elevation as a marker of progression of chronic heart failure. <i>Arterial Hypertension (Russian Federation)</i> , 2023, 28, 681-688. | 0.4 | 0 |
| 136 | Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review. <i>SeĀenovskij Vestnik</i> , 2023, 13, 4-13. | 0.4 | 0 |
| 137 | Āost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction. <i>Russian Journal of Cardiology</i> , 2023, 28, 5386. | 1.4 | 4 |
| 138 | Pathogenetic features of cardiovascular pathology in patients with osteoarthritis. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3416. | 1.4 | 0 |
| 139 | Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure. <i>Russian Archives of Internal Medicine</i> , 2023, 13, 14-23. | 0.2 | 4 |
| 140 | Features of post-infarction chronic heart failure in patients with a new coronavirus infection COVID-19. <i>Kazan Medical Journal</i> , 2023, 104, 20-29. | 0.2 | 0 |
| 141 | Diastolic dysfunction in late postmenopausal patients with undifferentiated connective tissue disease and hypertension. <i>Russian Journal of Cardiology</i> , 2023, 28, 5151. | 1.4 | 0 |
| 142 | The Value of Left Ventricular Mechanical Dyssynchrony and Scar Burden in the Combined Assessment of Factors Associated with Cardiac Resynchronization Therapy Response in Patients with CRT-D. <i>Journal of Clinical Medicine</i> , 2023, 12, 2120. | 2.4 | 0 |
| 143 | Diastolic dysfunction of the left and right ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2023, 61, 112-119. | 1.0 | 0 |
| 144 | Assessment Of Fluid Retention In Patients With Paroxysmal And Long-Standing Persistent Types Of Atrial Fibrillation. <i>Russian Open Medical Journal</i> , 2023, 12, . | 0.3 | 0 |
| 145 | Radiological microcirculatory findings in a relatively normal radiological picture of the lungs. <i>Regional Blood Circulation and Microcirculation</i> , 2023, 22, 5-15. | 0.3 | 0 |
| 146 | The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. <i>Pediatrician (St Petersburg)</i> , 2023, 14, 98-118. | 0.3 | 0 |
| 147 | Modern ideas about the role of the galaninergic system in the pathogenesis of heart failure and myocardial remodeling. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3546. | 1.4 | 2 |
| 148 | Diagnostic challenges of heart failure with preserved ejection fraction: focus on echocardiography. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3565. | 1.4 | 1 |
| 149 | CLINICAL AND PROGNOSTIC FEATURES OF ELDERLY PATIENTS WITH UNSTABLE ANGINA PECTORIS UNDERGOING CONSERVATIVE TREATMENT DEPENDING ON LEFT VENTRICULAR EJECTION FRACTION. <i>Complex Issues of Cardiovascular Diseases</i> , 2023, 12, 35-45. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 150 | Prospects for use of Vericiguat in HFREF: Implications of VICTORIA Trial Results. Advisory Board Summary. <i>Kardiologiya</i> , 2023, 63, 3-10. | 0.7 | 1 |
| 151 | Prognostic value of echocardiographic parameters of cardiac remodeling in patients with hypertension and obstructive sleep apnea. <i>Arterial Hypertension (Russian Federation)</i> , 2023, 29, 164-174. | 0.4 | 1 |
| 152 | Genetic factors of heart failure (review). <i>Sibirskij Å¾urnal KliniÄeskoj I ÅksperimentalÊnoj Mediciny</i> , 2023, 38, 38-43. | 0.4 | 1 |
| 153 | Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range. <i>Russian Journal of Cardiology</i> , 2023, 28, 5475. | 1.4 | 0 |
| 154 | Prognostic significance of NT-proBNP and sST2 biomarkers in patients with post-myocardial infarction heart failure after a coronavirus infection. <i>Russian Journal of Cardiology</i> , 2023, 28, 5216. | 1.4 | 0 |
| 155 | Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.. <i>Russian Journal of Cardiology</i> , 2023, 28, 5456. | 1.4 | 2 |
| 156 | The Role of rs2238296 of the Mitochondrial DNA Polymerase Gamma Gene in Combination with Polymorphic Variants of Antioxidant Defense Genes in the Development of Postinfarction Left Ventricular Aneurysm. <i>Russian Journal of Genetics</i> , 2023, 59, 97-103. | 0.6 | 0 |
| 157 | Associations of elevated levels of brain natriuretic peptide and heart failure and their contribution to survival in the Russian middle-aged population: data from the ESSE-RF study. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 22, 3553. | 1.4 | 1 |
| 158 | Peculiarities of geriatric status in patients with chronic heart failure over the age of 65: data from the EUCALYPTUS study. <i>Arterial Hypertension (Russian Federation)</i> , 2023, 29, 286-298. | 0.4 | 0 |
| 159 | High-sensitivity C-reactive protein as a predictor, indicator of severity and prognostic indicator of chronic heart failure. , 2023, 20, 16-21. | | 0 |
| 160 | A clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure in the entire spectrum of left ventricular ejection fraction in the Russian Federation. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 782-788. | 0.8 | 0 |
| 161 | Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation "PRIORITET-CHF": initial characteristics and treatment of the first included patients. <i>Russian Journal of Cardiology</i> , 2023, 28, 5593. | 1.4 | 0 |
| 162 | Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region. <i>Farmakoekonomika</i> , 2023, 16, 387-399. | 1.2 | 0 |
| 163 | Radiofrequency catheter ablation of sustained ventricular tachycardia in patients with coronary artery disease and chronic heart failure with left ventricular systolic dysfunction. (One-year) <i>Tj ETQq1 1 0.784314 rgt /Overlock 10 T 5</i> | | |
| 164 | Decompensated heart failure: a reconceptualization in the light of updated consensus statement of the European Society of Cardiology. <i>Russian Journal of Cardiology</i> , 2023, 28, 5581. | 1.4 | 0 |
| 165 | Diagnostic and clinical significance of cell free DNA levels in patients with chronic heart failure. <i>Medical and Social Expert Evaluation and Rehabilitation</i> , 2024, 26, 155-164. | 0.2 | 0 |
| 166 | Age and Sex Differences in Patients with Chronic Heart Failure. , 2024, , 134-142. | | 0 |
| 167 | The severity of chronic heart failure and the parameters of daily blood pressure profile in patients with coronary heart disease. <i>Exploration of Medicine</i> , 0, , 101-111. | 1.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 168 | Cognitive impairment in chronic heart failure. How new therapeutic options for the treatment of chronic heart failure affect cognitive function?. Eurasian Heart Journal, 2024, , 100-106. | 0.8 | 0 |